Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study

Kihyun Kim, Jae Hoon Lee, Jin Seok Kim, Chang Ki Min, Sung Soo Yoon, Kazuyuki Shimizu, Takaaki Chou, Hiroshi Kosugi, Kenshi Suzuki, Wenming Chen, Jian Hou, Jin Lu, Xiao Jun Huang, Shang Yi Huang, Wee Joo Chng, Daryl Tan, Gerrard Teoh, Chor Sang Chim, Weerasak Nawarawong, Noppadol SiritanaratkulBrian G. Durie

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P<0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first-line treatment. Am. J. Hematol. 89:751-756, 2014.

Original languageEnglish
Pages (from-to)751-756
Number of pages6
JournalAmerican Journal of Hematology
Volume89
Issue number7
DOIs
Publication statusPublished - 2014 Jul

Fingerprint

Multiple Myeloma
Survival Rate
Thalidomide
Survival
Incidence
Stem Cell Transplantation
Ethnic Groups
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kim, K., Lee, J. H., Kim, J. S., Min, C. K., Yoon, S. S., Shimizu, K., ... Durie, B. G. (2014). Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. American Journal of Hematology, 89(7), 751-756. https://doi.org/10.1002/ajh.23731
Kim, Kihyun ; Lee, Jae Hoon ; Kim, Jin Seok ; Min, Chang Ki ; Yoon, Sung Soo ; Shimizu, Kazuyuki ; Chou, Takaaki ; Kosugi, Hiroshi ; Suzuki, Kenshi ; Chen, Wenming ; Hou, Jian ; Lu, Jin ; Huang, Xiao Jun ; Huang, Shang Yi ; Chng, Wee Joo ; Tan, Daryl ; Teoh, Gerrard ; Chim, Chor Sang ; Nawarawong, Weerasak ; Siritanaratkul, Noppadol ; Durie, Brian G. / Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. In: American Journal of Hematology. 2014 ; Vol. 89, No. 7. pp. 751-756.
@article{31bee0e2e620445c97bc886316e13f6b,
title = "Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study",
abstract = "The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6{\%} of being male. Median overall survival (OS) was 47 months (95{\%} CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P<0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71{\%} including very good partial response or better in 31{\%} of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36{\%} of 2,970 patients and affected OS when used as a first-line treatment. Am. J. Hematol. 89:751-756, 2014.",
author = "Kihyun Kim and Lee, {Jae Hoon} and Kim, {Jin Seok} and Min, {Chang Ki} and Yoon, {Sung Soo} and Kazuyuki Shimizu and Takaaki Chou and Hiroshi Kosugi and Kenshi Suzuki and Wenming Chen and Jian Hou and Jin Lu and Huang, {Xiao Jun} and Huang, {Shang Yi} and Chng, {Wee Joo} and Daryl Tan and Gerrard Teoh and Chim, {Chor Sang} and Weerasak Nawarawong and Noppadol Siritanaratkul and Durie, {Brian G.}",
year = "2014",
month = "7",
doi = "10.1002/ajh.23731",
language = "English",
volume = "89",
pages = "751--756",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

Kim, K, Lee, JH, Kim, JS, Min, CK, Yoon, SS, Shimizu, K, Chou, T, Kosugi, H, Suzuki, K, Chen, W, Hou, J, Lu, J, Huang, XJ, Huang, SY, Chng, WJ, Tan, D, Teoh, G, Chim, CS, Nawarawong, W, Siritanaratkul, N & Durie, BG 2014, 'Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study', American Journal of Hematology, vol. 89, no. 7, pp. 751-756. https://doi.org/10.1002/ajh.23731

Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. / Kim, Kihyun; Lee, Jae Hoon; Kim, Jin Seok; Min, Chang Ki; Yoon, Sung Soo; Shimizu, Kazuyuki; Chou, Takaaki; Kosugi, Hiroshi; Suzuki, Kenshi; Chen, Wenming; Hou, Jian; Lu, Jin; Huang, Xiao Jun; Huang, Shang Yi; Chng, Wee Joo; Tan, Daryl; Teoh, Gerrard; Chim, Chor Sang; Nawarawong, Weerasak; Siritanaratkul, Noppadol; Durie, Brian G.

In: American Journal of Hematology, Vol. 89, No. 7, 07.2014, p. 751-756.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study

AU - Kim, Kihyun

AU - Lee, Jae Hoon

AU - Kim, Jin Seok

AU - Min, Chang Ki

AU - Yoon, Sung Soo

AU - Shimizu, Kazuyuki

AU - Chou, Takaaki

AU - Kosugi, Hiroshi

AU - Suzuki, Kenshi

AU - Chen, Wenming

AU - Hou, Jian

AU - Lu, Jin

AU - Huang, Xiao Jun

AU - Huang, Shang Yi

AU - Chng, Wee Joo

AU - Tan, Daryl

AU - Teoh, Gerrard

AU - Chim, Chor Sang

AU - Nawarawong, Weerasak

AU - Siritanaratkul, Noppadol

AU - Durie, Brian G.

PY - 2014/7

Y1 - 2014/7

N2 - The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P<0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first-line treatment. Am. J. Hematol. 89:751-756, 2014.

AB - The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P<0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first-line treatment. Am. J. Hematol. 89:751-756, 2014.

UR - http://www.scopus.com/inward/record.url?scp=84902775045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902775045&partnerID=8YFLogxK

U2 - 10.1002/ajh.23731

DO - 10.1002/ajh.23731

M3 - Article

C2 - 24723430

AN - SCOPUS:84902775045

VL - 89

SP - 751

EP - 756

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -